Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2022
Context: The Company, an emerging growth company, reported on regulatory developments regarding its lead product candidate, DMT310, for the treatment of acne and rosacea.
Key Financial Metrics
This filing does not contain comprehensive financial statements (revenue, profit, cash flow, or debt). The only specific financial figure disclosed is a potential cost saving of approximately $600,000 in development costs if the FDA grants a waiver for a 90-day dermal minipig study.
Material Changes and Regulatory Events
- Waiver Requests: The Company submitted requests to the FDA to waive requirements for a 90-day dermal minipig study and a standard dermal pharmacokinetic study prior to an End of Phase 2 meeting for the DMT310 acne program.
- Rationale: Requests are based on DMT310's acceptable safety profile in over 170 human patients and prior FDA approval for an ongoing 180-patient Phase 2 rosacea study.
- Historical Precedent: The FDA previously allowed DMT310 to proceed directly to human trials without the 90-day minipig study, citing the Botanical Drug Development Guidance.
Outlook, Risks, and Management Commentary
- Best Case Scenario: If both waivers are granted, the Company plans to request an End of Phase 2 meeting immediately and initiate the Phase 3 acne program in the second half of 2022.
- Partial Approval: If only the minipig study waiver is granted, the Company believes it can still complete the pharmacokinetic study and start Phase 3 in 2022.
- Risk of Delay: If the minipig study waiver is denied (regardless of the pharmacokinetic waiver status), the Phase 3 program may be delayed into 2023 due to supply chain constraints regarding the acquisition of required minipigs.
Investor Verification Checklist
- Confirm the FDA's decision on the waiver requests for the 90-day dermal minipig and pharmacokinetic studies.
- Monitor the timeline for the End of Phase 2 meeting and the subsequent initiation of the Phase 3 acne program.
- Assess the impact of potential 2023 delays on the Company's cash burn rate and liquidity position.
- Verify the status of the ongoing 180-patient Phase 2 rosacea study.